MoneyWorks4Me

Concord Biotech - Quaterly Results

01 Aug 2026 Evaluate
The sales figure stood at Rs. 2605.17 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 27.71% as compared to Rs. 2039.88 millions during the year-ago period.The company has announced a 43.76% increase in its profits to Rs . 611.94  millions for the  quarter ended June 2026 compared to Rs. 425.66 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 1002.72 millions compared to 750.75 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 2605.17 2039.88 27.71 2605.17 2039.88 27.71 10550.71 12000.87 -12.08
Other Income 130.96 136.78 -4.26 130.96 136.78 -4.26 527.31 444.47 18.64
PBIDT 1002.72 750.75 33.56 1002.72 750.75 33.56 4292.66 5507.79 -22.06
Interest 0.15 0.59 -74.58 0.15 0.59 -74.58 2.34 5.29 -55.77
PBDT 1002.57 750.16 33.65 1002.57 750.16 33.65 4257.57 5502.50 -22.62
Depreciation 180.47 177.76 1.52 180.47 177.76 1.52 743.25 543.74 36.69
PBT 822.10 572.40 43.62 822.10 572.40 43.62 3514.32 4958.76 -29.13
TAX 210.16 146.74 43.22 210.16 146.74 43.22 881.65 1229.11 -28.27
Deferred Tax 6.50 5.96 9.06 6.50 5.96 9.06 18.74 39.50 -52.56
PAT 611.94 425.66 43.76 611.94 425.66 43.76 2632.67 3729.65 -29.41
Equity 104.62 104.62 0.00 104.62 104.62 0.00 104.62 104.62 0.00
PBIDTM(%) 38.49 36.80 4.58 38.49 36.80 4.58 40.69 45.89 -11.35

Concord Biotech Share Price

1520.85 74.75 (5.17%)
17-Aug-2026 15:52 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1882.50
Dr. Reddys Labs. 1192.00
Cipla 1430.00
Lupin 2259.20
Zydus Lifesciences 1132.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: